Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Rhea-AI Summary
Sagimet Biosciences (Nasdaq: SGMT) announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The clinical-stage biopharmaceutical company, which develops therapeutics for metabolic and fibrotic pathways, will present on Tuesday, December 3, 2024 at 10 a.m. EST in New York City. A webcast will be accessible through Sagimet's website, with replay available for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SGMT gained 4.87%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 10 a.m. EST in New York City, New York.
A webcast of the presentation will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit www.sagimet.com.
Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Source: Sagimet Biosciences Inc.
FAQ
When is Sagimet Biosciences (SGMT) presenting at the Piper Sandler Healthcare Conference?
How long will the Sagimet Biosciences (SGMT) Piper Sandler Conference webcast be available?
Where can I watch Sagimet Biosciences' (SGMT) Piper Sandler Conference presentation?
What type of therapeutics does Sagimet Biosciences (SGMT) develop?
